Divastin Plus5 mg+10 mg

Divastin Plus is a fixed-dose combination indicated in patients for whom treatment with both a calcium channel blocker (amlodipine) and an HMG-CoA reductase inhibitor/statin (atorvastatin) is considered appropriate.

Established/FDA-approved uses

• Hypertension: Divastin Plus is used to treat high blood pressure in patients who also require lipid-lowering therapy.
• Hypercholesterolemia and mixed dyslipidemia: Divastin Plus is used to reduce elevated total cholesterol, LDL-cholesterol, apolipoprotein B, and triglycerides, and to increase HDL-cholesterol, in patients who also require blood pressure control.
• Cardiovascular risk reduction: in appropriate patients with both hypertension and dyslipidemia (with or without evident coronary heart disease), Divastin Plus is used as part of an overall strategy to reduce the risk of myocardial infarction, stroke, and other cardiovascular events.

Requires combination therapy

Divastin Plus is only appropriate when a patient independently needs both an antihypertensive calcium channel blocker and a statin; it is not intended for patients who need only one of the two components.

Divastin Plus should always be used alongside diet, exercise, and other lifestyle modifications as advised by a physician.

Amlodipine + Atorvastatin is a fixed-dose combination tablet containing:

• Amlodipine (as amlodipine besylate) — a dihydropyridine calcium channel blocker.
• Atorvastatin (as atorvastatin calcium) — an HMG-CoA reductase inhibitor (statin).

Amlodipine + Atorvastatin tablets are available in multiple strength combinations of amlodipine and atorvastatin (for example, amlodipine 5 mg or 10 mg combined with atorvastatin 10 mg, 20 mg, 40 mg, or 80 mg), allowing dose individualization based on a patient's blood pressure and lipid targets.

Divastin Plus combines two medicines that act on two different cardiovascular risk factors in a single tablet.

Amlodipine is a long-acting dihydropyridine calcium channel blocker that relaxes vascular smooth muscle, dilates peripheral arteries, and lowers blood pressure. Atorvastatin is a statin that inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis, thereby lowering LDL-cholesterol and triglycerides while raising HDL-cholesterol.

By combining an antihypertensive with a lipid-lowering agent, Divastin Plus simplifies treatment for patients who need both types of therapy for overall cardiovascular risk reduction.

Divastin Plus belongs to a combination therapeutic class comprising:

• Calcium channel blocker (dihydropyridine class) — antihypertensive/antianginal agent.
• HMG-CoA reductase inhibitor (statin class) — lipid-lowering agent.

Divastin Plus is therefore classified as an antihypertensive–antihyperlipidemic fixed-dose combination.

Amlodipine component

Amlodipine inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle by blocking L-type calcium channels. This produces relaxation of vascular smooth muscle (vasodilation), reducing peripheral vascular resistance and blood pressure, with a gradual onset of action and a long half-life allowing once-daily dosing.

Atorvastatin component

Atorvastatin selectively and competitively inhibits HMG-CoA reductase, the enzyme that converts HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis. This reduces hepatic cholesterol content, upregulates hepatic LDL-receptor expression, and increases clearance of LDL from the bloodstream, resulting in reductions in LDL-cholesterol, total cholesterol, apolipoprotein B, and triglycerides, and modest increases in HDL-cholesterol.

Amlodipine + Atorvastatin combines these two complementary mechanisms of action in one tablet, addressing blood pressure and lipid abnormalities together.

Divastin Plus is taken orally, once daily, with or without food, at approximately the same time each day to maintain steady blood levels. Tablets should be swallowed whole and not crushed or chewed unless a physician has advised otherwise.

Divastin Plus carries a combined interaction profile from both its amlodipine and atorvastatin components. Report all prescription, over-the-counter, and herbal products to your physician before starting Divastin Plus.

Clinically significant interactions

• Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, ketoconazole, certain HIV protease inhibitors): may substantially increase plasma levels of both amlodipine and atorvastatin, raising the risk of hypotension, peripheral edema, and myopathy/rhabdomyolysis. Concomitant use should be avoided or requires dose adjustment and close monitoring.
• Cyclosporine: significantly increases atorvastatin exposure; concomitant use with Divastin Plus is generally not recommended.
• Gemfibrozil, other fibrates, and niacin (lipid-lowering doses): additive risk of myopathy and rhabdomyolysis when combined with the atorvastatin component of Divastin Plus; combination should be avoided or used only with careful risk-benefit assessment and monitoring.
• Grapefruit juice: large quantities (more than about 1.2 liters/day) can increase atorvastatin blood levels; excessive grapefruit juice consumption should be avoided while taking Divastin Plus.
• Digoxin: amlodipine may modestly increase plasma digoxin concentrations; monitor digoxin levels and for signs of toxicity when co-administered with Divastin Plus.
• Other antihypertensives: the amlodipine component of Divastin Plus may have additive blood-pressure-lowering effects with other antihypertensive agents, requiring monitoring for excessive hypotension.

Most patients tolerate Divastin Plus well, but side effects can occur from either component.

Common side effects

• Peripheral edema (swelling of the ankles/feet)
• Flushing and sensation of warmth
• Headache
• Dizziness or lightheadedness
• Muscle aches (myalgia)
• Mild elevations in liver enzymes
• Nausea, indigestion, diarrhea, or constipation
• Nasopharyngitis, joint pain

Serious but rare side effects

• Myopathy and rhabdomyolysis: unexplained muscle pain, tenderness, or weakness accompanied by markedly elevated creatine kinase, which can rarely progress to serious muscle breakdown and kidney injury. Seek medical attention promptly if this occurs.
• Hepatotoxicity: rare but serious liver injury, which may present as fatigue, loss of appetite, jaundice, dark urine, or right upper abdominal pain.
• Significant swelling, palpitations, or fainting related to the amlodipine component.
• Allergic reactions (rash, itching, swelling of the face/lips/tongue, difficulty breathing).

Contact your physician promptly if you notice any serious or persistent side effects while taking Divastin Plus.

Divastin Plus is contraindicated in pregnancy. The atorvastatin component may cause fetal harm, as cholesterol and cholesterol biosynthesis products are essential for fetal development; statins provide no known benefit during pregnancy. If a patient becomes pregnant while taking Divastin Plus, the medicine should be discontinued immediately and the physician informed.

Women of reproductive potential should use effective contraception while taking Divastin Plus. If pregnancy is planned, Divastin Plus should be stopped in advance and alternative management discussed with a physician.

Divastin Plus is contraindicated during breastfeeding. It is not known whether amlodipine passes into breast milk in clinically significant amounts, but the atorvastatin component is contraindicated during lactation due to the potential for serious adverse effects in the nursing infant. Women who require Divastin Plus should not breastfeed, and physicians should help identify alternative feeding or treatment strategies.

Myopathy and rhabdomyolysis

Divastin Plus contains atorvastatin, which like other statins can rarely cause myopathy and, very rarely, life-threatening rhabdomyolysis with acute kidney injury. Risk is increased with advanced age, renal impairment, hypothyroidism, and concomitant use of interacting drugs (see Interactions). Patients should report unexplained muscle pain, tenderness, or weakness immediately, especially if accompanied by fever or dark urine. Divastin Plus should be discontinued if myopathy is diagnosed or suspected, or if creatine kinase levels are markedly elevated.

Hepatotoxicity

Liver enzyme abnormalities have occurred with statin use. Liver function tests are recommended before starting Divastin Plus and as clinically indicated thereafter. Divastin Plus should be used with caution in patients with a history of liver disease or substantial alcohol use, and is contraindicated in active liver disease (see Contraindications).

Hypotension and cardiovascular caution

The amlodipine component of Divastin Plus can cause symptomatic hypotension, particularly in patients with severe aortic stenosis, and should be used cautiously in patients with severe hypotension, unstable angina, or heart failure, as it may occasionally increase the frequency, duration, or severity of angina or precipitate a myocardial infarction, particularly at treatment initiation or dose increase.

Pregnancy

See Pregnancy and Lactation — Divastin Plus is contraindicated in pregnancy due to the atorvastatin component.

General

Do not stop Divastin Plus abruptly without consulting your physician. Regular follow-up, including blood pressure checks and periodic lipid and liver function monitoring, is recommended during treatment with Divastin Plus.

Overdose of Divastin Plus may cause excessive peripheral vasodilation with marked and prolonged systemic hypotension, reflex tachycardia, and possible shock, related to the amlodipine component; specific effects of acute atorvastatin overdose are not well characterized but are not expected to be life-threatening based on available data.

If an overdose of Divastin Plus is suspected, seek immediate medical attention or contact a poison control center/emergency services right away. Do not attempt to treat an overdose at home. Supportive care, including cardiovascular monitoring and treatment, will be provided by medical professionals; there is no specific antidote for either component of Divastin Plus.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly patients

No overall dosage adjustment of Divastin Plus is required based on age alone, but elderly patients may be more sensitive to the blood-pressure-lowering effects of amlodipine and are at higher risk of statin-associated myopathy; use with routine caution and monitoring.

Renal impairment

No dose adjustment of Divastin Plus is generally required, though patients with significant renal impairment should be monitored (see Dosage and Administration).

Hepatic impairment

Divastin Plus should be used cautiously in hepatic impairment and is contraindicated in active liver disease (see Contraindications and Dosage and Administration).

Pediatric use

See Pediatric Uses — safety and effectiveness of Divastin Plus as a fixed-dose combination have not been established in pediatric patients.

Pregnancy and lactation

See Pregnancy and Lactation — Divastin Plus is contraindicated in both pregnancy and breastfeeding.

Divastin Plus is generally used as a long-term, ongoing treatment for chronic hypertension and dyslipidemia, since both conditions typically require continuous management to sustain blood pressure control and cardiovascular risk reduction. Duration of therapy should be determined by a physician based on periodic reassessment of blood pressure, lipid profile, and tolerability, and Divastin Plus should not be stopped without medical advice.

Calcium channel blocker (dihydropyridine) combined with HMG-CoA reductase inhibitor (statin); antihypertensive–antihyperlipidemic fixed-dose combination.

Amlodipine + Atorvastatin works through two independent, complementary mechanisms. Amlodipine blocks L-type calcium channels in vascular smooth muscle, reducing calcium influx and causing vasodilation, which lowers systemic vascular resistance and blood pressure. Atorvastatin inhibits HMG-CoA reductase, reducing hepatic cholesterol synthesis and upregulating LDL receptors, which increases clearance of LDL-cholesterol from the blood and improves the overall lipid profile.

X

The safety and effectiveness of Divastin Plus as a fixed-dose combination tablet have not been established in pediatric patients. Divastin Plus should generally not be used in children.

When individually appropriate and prescribed by a specialist, amlodipine alone has been studied for hypertension in children aged 6 to 17 years, and atorvastatin alone is approved for certain pediatric patients aged 10 years and older with specific inherited high-cholesterol conditions; however, this does not extend to the combined Divastin Plus product, which should not be used in pediatric patients outside of specific specialist guidance.